| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Theravance Biopharma, Inc. (TBPH) has 11 insiders with recent SEC Form 4 filings, including 8 buys and 0 sells. TBPH is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 1.65M | $27.19M | - | |
| VP | 355.3K | $5.85M | - | |
| CFO | 336.8K | $5.55M | - | |
| VP | 242.4K | $3.99M | -13,314 | |
| VP | 201.0K | $3.31M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Mar 14, 2016 | Glaxosmithkline Plc | 10% Owner | Buy | 1,301,015 | $0.00 | - | +15.6% | |
| Oct 7, 2015 | Glaxosmithkline Plc | 10% Owner | Buy | 44,574 | $0.00 | - | +0.5% | |
| Aug 18, 2015 | Lee Junning | Sr. VP, Technical Operations | Buy | 9,000 | $12.90 | $116,100.00 | New | |
| Aug 18, 2015 | Malkiel Burton G | Director | Buy | 10,000 | $12.92 | $129,200.00 | +94.6% | |
| Aug 17, 2015 | Winningham Rick E64 | Chief Executive Officer | Buy | 80,000 | $11.86 | $948,932.40 | +7.2% | |
| Aug 17, 2015 | Gala Renee D | SVP, Chief Financial Officer | Buy | 10,000 | $12.18 | $121,750.00 | +3.3% |